GSK settles Avandia lawsuits ahead of Philadelphia trial
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has settled the first case scheduled for trial in the US over claims that the company's diabetes drug Avandia (rosiglitazone) increases the risks of heart attack or other ischaemic cardiovascular events. The trial was due to start in a Philadelphia court on 1 June.